These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30878206)

  • 21. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study.
    Lindor KD; Jorgensen RA; Anderson ML; Gores GJ; Hofmann AF; LaRusso NF
    Am J Gastroenterol; 1996 Mar; 91(3):511-5. PubMed ID: 8633500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey.
    Okolicsanyi L; Groppo M; Floreani A; Morselli-Labate AM; Rusticali AG; Battocchia A; Colombo M; Galatola G; Gasbarrini G; Podda M; Ricci G; Rosina F; Zuin M
    Dig Liver Dis; 2003 May; 35(5):325-31. PubMed ID: 12846404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period.
    Stiehl A; Walker S; Stiehl L; Rudolph G; Hofmann WJ; Theilmann L
    J Hepatol; 1994 Jan; 20(1):57-64. PubMed ID: 8201224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study.
    Eaton JE; Nelson KM; Gossard AA; Carey EJ; Tabibian JH; Lindor KD; LaRusso NF
    Scand J Gastroenterol; 2019 May; 54(5):633-639. PubMed ID: 31131678
    [No Abstract]   [Full Text] [Related]  

  • 25. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis.
    Harnois DM; Angulo P; Jorgensen RA; Larusso NF; Lindor KD
    Am J Gastroenterol; 2001 May; 96(5):1558-62. PubMed ID: 11374699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.
    Imam MH; Sinakos E; Gossard AA; Kowdley KV; Luketic VA; Edwyn Harrison M; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Keach J; DeCook AC; Enders F; Lindor KD
    Aliment Pharmacol Ther; 2011 Nov; 34(10):1185-92. PubMed ID: 21957881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of cholestatic liver disease].
    Pleşa A
    Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):733-6. PubMed ID: 14756010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
    Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
    J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis.
    Stanich PP; Björnsson E; Gossard AA; Enders F; Jorgensen R; Lindor KD
    Dig Liver Dis; 2011 Apr; 43(4):309-13. PubMed ID: 21251891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
    Trauner M; Gulamhusein A; Hameed B; Caldwell S; Shiffman ML; Landis C; Eksteen B; Agarwal K; Muir A; Rushbrook S; Lu X; Xu J; Chuang JC; Billin AN; Li G; Chung C; Subramanian GM; Myers RP; Bowlus CL; Kowdley KV
    Hepatology; 2019 Sep; 70(3):788-801. PubMed ID: 30661255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
    Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P
    Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ursodeoxycholic acid is associated with improved long-term outcome in patients with primary sclerosing cholangitis.
    Arizumi T; Tazuma S; Isayama H; Nakazawa T; Tsuyuguchi T; Takikawa H; Tanaka A;
    J Gastroenterol; 2022 Nov; 57(11):902-912. PubMed ID: 36068441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ursodeoxycholic acid therapy in treatment of primary sclerosing cholangitis.
    Stiehl A
    Scand J Gastroenterol Suppl; 1994; 204():59-61. PubMed ID: 7824879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bile acids for primary sclerosing cholangitis.
    Chen W; Gluud C
    Cochrane Database Syst Rev; 2003; (2):CD003626. PubMed ID: 12804480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.
    Colombo C; Battezzati PM; Podda M; Bettinardi N; Giunta A
    Hepatology; 1996 Jun; 23(6):1484-90. PubMed ID: 8675168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of Ursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis with Ulcerative Colitis: A Pediatric Case.
    Fujita Y; Sugaya T; Inui A; Yoshihara S
    Tohoku J Exp Med; 2021 Feb; 253(2):109-112. PubMed ID: 33551380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
    Smith T; Befeler AS
    Curr Gastroenterol Rep; 2007 Mar; 9(1):54-9. PubMed ID: 17335678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of ursodeoxycholic acid therapy in chronic viral hepatitis C with high serum gamma-glutamyltranspeptidase levels.
    Kiso S; Kawata S; Imai Y; Tamura S; Inui Y; Ito N; Matsuzawa Y
    J Gastroenterol; 1996 Feb; 31(1):75-80. PubMed ID: 8808432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study.
    Rolandi E; Franceschini R; Cataldi A; Cicchetti V; Carati L; Barreca T
    Eur J Clin Pharmacol; 1991; 40(5):473-6. PubMed ID: 1679391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A dose-up of ursodeoxycholic acid decreases transaminases in hepatitis C patients.
    Sato S; Miyake T; Tobita H; Oshima N; Ishine J; Hanaoka T; Amano Y; Kinoshita Y
    World J Gastroenterol; 2009 Jun; 15(22):2782-6. PubMed ID: 19522030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.